<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="72191">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01897142</url>
  </required_header>
  <id_info>
    <org_study_id>B2341001</org_study_id>
    <nct_id>NCT01897142</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-05230907 In Healthy Volunteers</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Sponsor-Open, Placebo-Controlled, Single Ascending Dose Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-05230907 In Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine what the study drug does to the body, what the
      body does to the study drug, and if the study drug is safe and well tolerated when given to
      adult healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Incidence of dose limiting treatment related adverse events</measure>
    <time_frame>Through Day 43</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence, severity and causal relationship of treatment emergent adverse events, treatment emergent serious adverse events, and withdrawals due to treatment emergent adverse events</measure>
    <time_frame>Through Day 43</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and magnitude of treatment emergent abnormal laboratory findings</measure>
    <time_frame>Through Day 43</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in vital sign measurements, ECG parameters, and physical examinations</measure>
    <time_frame>Through Day 43</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)</measure>
    <time_frame>Through 4 hour post dose Day 1</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>Through 4 hour post dose Day 1</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax)</measure>
    <time_frame>Through 4 hour post dose Day 1</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution at Steady State (Vss)</measure>
    <time_frame>Through 4 hour post dose Day 1</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Clearance (CL)</measure>
    <time_frame>Through 4 hour post dose Day 1</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half -life</measure>
    <time_frame>Through 4 hour post dose Day 1</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean residence Time (MRT)</measure>
    <time_frame>Through 4 hour post dose Day 1</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution during terminal phase (Vz)</measure>
    <time_frame>Through 4 hour post dose Day 1</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve from time zero to infinity (AUC inf)</measure>
    <time_frame>Through 4 hour post dose Day 1</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic activity as measured by prothrombin time/internationalize normalized ration (PT/INR)</measure>
    <time_frame>Through post dose Day3</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic activity as measured by activated partial thromboplastin time (aPTT) or partial thromboplastin time (PTT)</measure>
    <time_frame>Through post dose Day3</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic activity as measured by thrombin-antithrombin (TAT) complexes</measure>
    <time_frame>Through post dose Day 2</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic activity as measured by prothrombin fragments 1+2 (PF1+2)</measure>
    <time_frame>Through post dose Day 2</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic activity as measured by D-dimer</measure>
    <time_frame>Through post dose Day 7</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic activity as measured by protein C activity</measure>
    <time_frame>Through post dose Day 2</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic activity as measured by Factor V activity</measure>
    <time_frame>Through post dose Day 3</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of antibody immune response</measure>
    <time_frame>Through post dose Day 43</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Factor X activity</measure>
    <time_frame>Through post dose Day 43</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>PF-05230907 and Placebo Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-05230907 and Placebo Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-05230907 and Placebo Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-05230907 and Placebo Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-05230907 and Placebo Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-05230907 and Placebo Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-05230907</intervention_name>
    <description>0.1 micrograms per kilogram of PF-05230907, IV bolus, single dose</description>
    <arm_group_label>PF-05230907 and Placebo Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for PF-05230907</intervention_name>
    <description>0.1 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose</description>
    <arm_group_label>PF-05230907 and Placebo Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-05230907</intervention_name>
    <description>0.3 micrograms per kilogram of PF-05230907, IV bolus, single dose</description>
    <arm_group_label>PF-05230907 and Placebo Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for PF-05230907</intervention_name>
    <description>0.3 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose</description>
    <arm_group_label>PF-05230907 and Placebo Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-05230907</intervention_name>
    <description>1 micrograms per kilogram of PF-05230907, IV bolus, single dose</description>
    <arm_group_label>PF-05230907 and Placebo Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for PF-05230907</intervention_name>
    <description>1 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose</description>
    <arm_group_label>PF-05230907 and Placebo Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-05230907</intervention_name>
    <description>2 micrograms per kilogram of PF-05230907, IV bolus, single dose</description>
    <arm_group_label>PF-05230907 and Placebo Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for PF-05230907</intervention_name>
    <description>2 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose</description>
    <arm_group_label>PF-05230907 and Placebo Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-05230907</intervention_name>
    <description>4 micrograms per kilogram of PF-05230907, IV bolus, single dose</description>
    <arm_group_label>PF-05230907 and Placebo Cohort 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for PF-05230907</intervention_name>
    <description>4 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose</description>
    <arm_group_label>PF-05230907 and Placebo Cohort 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-05230907</intervention_name>
    <description>8 micrograms per kilogram of PF-05230907, IV bolus, single dose</description>
    <arm_group_label>PF-05230907 and Placebo Cohort 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for PF-05230907</intervention_name>
    <description>8 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose</description>
    <arm_group_label>PF-05230907 and Placebo Cohort 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subjects.

          -  Healthy non-child bearing female subjects.

          -  18 to 35 years of age.

        Exclusion Criteria:

          -  Heart disease.

          -  Clotting disorders.

          -  Use of nicotine products.

          -  Diabetes.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Brussels</city>
        <zip>B-1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B2341001&amp;StudyName=A%20Phase%201%20Study%20To%20Evaluate%20The%20Safety%2C%20Tolerability%2C%20Pharmacokinetics%20And%20Pharmacodynamics%20Of%20Pf-05230907%20In%20Healthy%20Volunteers</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 28, 2014</lastchanged_date>
  <firstreceived_date>June 24, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
